Paxlovid and Other COVID-19 Meds Will Soon Have Big Price Tags
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
MONDAY, Oct. 30, 2023 -- Americans have been getting COVID-19 treatments such as Paxlovid for free, but that is about to end. The medications will enter the private market this week, the Associated Press reported.
The price for a five-day course of Paxlovid, made by Pfizer, will be $1,390. Merck has not confirmed a price for its COVID-19 treatment, Lagevrio, but told the AP that it will offer the treatment free to patients "who, without assistance, could not otherwise afford the product."
The pills will still be available at no cost until those bought earlier by the federal government run out at pharmacies, hospitals, and doctors' offices, according to U.S. Health and Human Services officials. The government paid Pfizer $5 billion for 10 million courses of Paxlovid in 2021. Once those are gone, those with private insurance may notice a copay charge, the AP reported.
People on Medicaid or Medicare or without medical insurance will not pay any out-of-pocket costs for these treatments through 2024, and Pfizer will offer copay assistance for Paxlovid through 2028.
The Department of Veterans Affairs, Department of Defense, and Indian Health Service will still have access to government stores of Paxlovid, the AP reported. The federal government will also keep 1 million treatment courses in its stockpile.
Medical suppliers can begin ordering the treatment from the drug companies starting this week.
Associated Press Article
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Further Support and Information on COVID-19
Read this next
Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season
WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...
Global Life Expectancy, Disease Burden Set to Keep Improving
WEDNESDAY, May 22, 2024 -- Life expectancy and age-standardized disease burden are expected to continue improving between 2022 and 2050, according to the Global Burden of Disease...
Long COVID Definitions, Care Models Are Evolving
MONDAY, May 20, 2024 -- Definitions of long COVID and care models are evolving, but considerable variability is seen in these models, according to a review published online May 21...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.